Loading…
Employees: 162
Size Alebund Pharmaceuticals (Jiangsu) (9637.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $576M, the 728th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$19.18 on 6 Nov 2026.
Growth Revenue grew 673.9% over the last twelve months (peer median +3.1%); the operating margin is -494.9% (peer median -9.5%).
Valuation It trades at 25.7× enterprise value to sales against a peer median of 6.7× (3rd most expensive of 15).
Capital Return on invested capital runs 89.1 points below its cost of capital (5.2% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | HK$139M | HK$33.1M | HK$7.07M | HK$0 |
| Revenue growth | — | +368% | — | — |
| Gross profit | HK$69.5M | -HK$29.8M | -HK$9.87M | -HK$12.8M |
| EBITDA | -HK$636M | -HK$653M | -HK$323M | -HK$399M |
| Net income | -HK$778M | -HK$813M | -HK$353M | -HK$403M |
| Free cash flow | -HK$479M | -HK$443M | -HK$537M | -HK$552M |
| Capital expenditure | HK$80.7M | HK$110M | HK$257M | HK$222M |
| Total debt | n/a | HK$612M | HK$510M | HK$203M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9637.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -32.9% | -14.7% | 3rd lowest of 21 |
| Distance from 52-week high | -59.0% | -44.9% | 3rd lowest of 21 |
| Revenue growth (TTM) | +673.9% | +3.1% | highest of 15 |
| Operating margin | -494.9% | -9.5% | 2nd lowest of 15 |
| EV / Sales | 25.7× | 6.7× | 3rd most expensive of 15 |
| ROIC minus cost of capital | -89.1 pp | -3.5 pp | 2nd lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $576M | n/a | +674% | -495% | 25.7× | n/a | n/a |
| Faeth Therapeutics FTH | United States | $570M | -6% | n/a | n/a | n/a | n/a | n/a |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 11.2× | 40.0% | +143.5% |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $554M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $553M | -19% | +6% | -11% | 6.5× | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | 2,088.7× | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $537M | -14% | -17% | 0% | 7.0× | 31.6% | +7.0% |
| Valneva VLA.PA | France | $534M | -2% | -27% | -87% | 4.0× | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $531M | -33% | +2% | 17% | 2.2× | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $530M | -15% | +70% | 5% | 5.4× | n/a | n/a |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | 20.3× | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $526M | -25% | +4% | 8% | 8.0× | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 1.6× | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | 2.0× | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | 2.7× | -8.3% | -1.3% |
| HanchorBio 7827.TW | Taiwan | $511M | n/a | n/a | -225% | 48.0× | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $507M | -11% | -1% | 26% | 13.7× | n/a | n/a |
| Neurogene NGNE | United States | $506M | -18% | -100% | n/a | n/a | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $505M | +48% | n/a | n/a | n/a | n/a | n/a |